Haier Biomedical Reports Record Overseas Revenue in 2025 Annual Results

Haier Biomedical announced in a press release that it achieved full year revenue of 2.33 billion yuan (about 340.77 million USD) in 2025, with overseas revenue rising 17.9 percent year on year to 840 million yuan. Overseas operations accounted for 36 percent of total revenue, marking a record high for the company.

According to the report, Haier Biomedical recorded double digit growth across all international business regions, including 26 percent growth in the Asia Pacific region and 16 percent in Europe. New business sectors such as smart medication, blood technology, and laboratory solutions contributed nearly half of total revenue. Revenue from AI powered applications reached 15 percent of the total, an increase of 2.5 percentage points from 2024.

The company noted that its ultra low temperature biomedical freezers ranked first in market share in six countries, and its plasma separation system became the first Chinese solution to obtain EU MDR certification. In 2025, research and development investment reached 320 million yuan with 1,620 new invention patents, up 50 percent year on year.

Haier Biomedical also introduced its three year “543” strategic plan, which aims for overseas revenue to exceed 50 percent, for acquired businesses to contribute at least 40 percent of future revenue, and for AI related revenue to reach over 30 percent. The company said it will continue to expand localized operations and pursue AI driven innovation and acquisitions to strengthen its global presence.